”The regulation will dramatically reduce duplications of clinical assessments, ensure sustainable cooperation on HTA and provide us with a framework to better face health issues, such as rare diseases, personal medicine and orphan medicines.”

Tiemo Wölken MEP, European Parliament Rapporteur

Article published 4 May 2022.